share_log

China Meheco Group's (SHSE:600056) Profits Appear To Have Quality Issues

China Meheco Group's (SHSE:600056) Profits Appear To Have Quality Issues

中国医药集团(SHSE:600056)的利润似乎存在质量问题
Simply Wall St ·  2024/11/05 06:02

China Meheco Group Co., Ltd.'s (SHSE:600056) healthy profit numbers didn't contain any surprises for investors. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

中国医药集团有限公司(SHSE:600056)健康的利润数字并没有给投资者带来任何惊喜。我们相信股东已经注意到一些超出法定利润数字的令人关注的因素。

big
SHSE:600056 Earnings and Revenue History November 4th 2024
上证所:600056 盈利和营业收入历史 2024年11月4日

The Impact Of Unusual Items On Profit

非正常项目对利润的影响

For anyone who wants to understand China Meheco Group's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥479m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. We can see that China Meheco Group's positive unusual items were quite significant relative to its profit in the year to September 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

对于任何想要了解中国医药集团利润的人来说,重要的是要注意,在过去的十二个月里,法定利润中有47900万CN¥来自于飞凡项目。虽然利润更高总是让人开心,但飞凡项目的巨大贡献有时会降低我们的热情。当我们对数千家上市公司的数据进行分析时,我们发现某一年来自飞凡项目的增长通常在下一年不会重现。毕竟,这正是会计术语的含义。我们可以看到,在截至2024年9月的年度里,中国医药集团的正向飞凡项目相对于其利润而言非常显著。其他条件相同,这可能会使法定利润成为衡量潜在盈利能力的一个不好的指标。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of China Meheco Group.

注意:我们始终建议投资者检查资产负债表的实力。点击这里查看我们对中国医药集团资产负债表分析。

Our Take On China Meheco Group's Profit Performance

我们对中国医药集团的利润表现看法

As we discussed above, we think the significant positive unusual item makes China Meheco Group's earnings a poor guide to its underlying profitability. For this reason, we think that China Meheco Group's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. The good news is that, its earnings per share increased by 60% in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. To help with this, we've discovered 3 warning signs (1 is a bit unpleasant!) that you ought to be aware of before buying any shares in China Meheco Group.

正如我们上面所讨论的,我们认为显著的积极异常项使中国医药集团的收益并不能很好地反映其潜在盈利能力。因此,我们认为中国医药集团的法定利润可能并不能很好地代表其潜在的盈利能力,并可能给投资者带来过于乐观的公司印象。好消息是,去年的每股收益增长了60%。当然,我们在分析其收益时仅仅是触及了表面;还可以考虑利润率、预测增长和投资回报率等其他因素。鉴于此,如果您想对公司进行更多分析,了解所涉及的风险至关重要。为此,我们发现了3个警示信号(其中一个稍显不愉快!),在您购买任何中国医药集团的股票之前,您应该了解这些信号。

This note has only looked at a single factor that sheds light on the nature of China Meheco Group's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

本说明仅考察了一个单一因素,该因素反映了中国医药集团利润的本质。但是,如果您能够专注于细节,总有更多的东西可以发现。有些人认为高股本回报率是优质业务的好迹象。虽然这可能需要您进行一些研究,但您可能会发现这一免费公司集合高回报率,或这一显著内部持有的股票名单对您有帮助。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发